Swiftmerge Acquisition Long-Term Investments 2022-2024 | IVCP

Swiftmerge Acquisition long-term investments from 2022 to 2024. Long-term investments can be defined as the aggregate value of debt and or equity investments with maturities or benefits lasting more than one year.

Swiftmerge Acquisition Long-Term Investments 2022-2024 | IVCP

Swiftmerge Acquisition long-term investments from 2022 to 2024. Long-term investments can be defined as the aggregate value of debt and or equity investments with maturities or benefits lasting more than one year.
Related Stocks
Company NameMarket
Cap
Zoetis (ZTS)$86.1B
Takeda Pharmaceutical (TAK)$45.9B
Merck (MKGAF)$21.6B
Astellas Pharma (ALPMY)$21.1B
Sandoz Group AG (SDZNY)$17.8B
United Therapeutics (UTHR)$15.8B
Summit Therapeutics (SMMT)$13.8B
Shionogi (SGIOY)$12.6B
Neurocrine Biosciences (NBIX)$11.5B
Catalent (CTLT)$11B
Orion OYJ (ORINY)$8B
Jazz Pharmaceuticals (JAZZ)$6.8B
Ionis Pharmaceuticals (IONS)$5.5B
Hikma Pharmaceuticals Plc (HKMPF)$5.5B
Corcept Therapeutics (CORT)$4.7B
Madrigal Pharmaceuticals (MDGL)$4.5B
Crinetics Pharmaceuticals (CRNX)$4.3B
Dyne Therapeutics (DYN)$3.3B
PTC Therapeutics (PTCT)$2.7B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.7B
Catalyst Pharmaceuticals (CPRX)$2.4B
Arrowhead Pharmaceuticals (ARWR)$2.3B
Soleno Therapeutics (SLNO)$1.9B
Centessa Pharmaceuticals (CNTA)$1.8B
Harrow (HROW)$1.8B
Recursion Pharmaceuticals (RXRX)$1.7B
NewAmsterdam Pharma (NAMS)$1.6B
Ardelyx (ARDX)$1.6B
BioCryst Pharmaceuticals (BCRX)$1.6B
Ocular Therapeutix (OCUL)$1.5B